Pizzuti Dana, Chief Medical and Development Officer at Crinetics Pharmaceuticals ($CRNX), sold nearly $2 million worth of shares through 9 open market transactions over the past year. Her most recent sale occurred on December 1, 2025. These sales rank her 3,505th among 11,678 insiders by total value sold, below the average of about $8.6 million per seller and 6.4 transactions. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 1, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 5000 | $16.89 | 71,837.0000 | 94,548,000 | 7.48% | 0.01% |
| Dec. 1, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 69,042.0000 | 94,548,000 | 6.75% | 0.01% |
| Dec. 1, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 5000 | $45.02 | 66,837.0000 | 94,548,000 | 6.96% | 0.01% |
| Nov. 3, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 5000 | $16.89 | 71,270.0000 | 94,548,000 | 7.54% | 0.01% |
| Nov. 3, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 4900 | $42.65 | 66,370.0000 | 94,548,000 | 6.88% | 0.01% |
| Nov. 3, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 74,042.0000 | 94,548,000 | 6.33% | 0.01% |
| Nov. 3, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 100 | $43.27 | 66,270.0000 | 94,548,000 | 0.15% | 0.00% |
| Oct. 1, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 5000 | $41.81 | 66,270.0000 | 94,548,000 | 7.02% | 0.01% |
| Oct. 1, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 79,042.0000 | 94,548,000 | 5.95% | 0.01% |
| Oct. 1, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 5000 | $16.89 | 71,270.0000 | 94,548,000 | 7.54% | 0.01% |
| Sept. 2, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 84,042.0000 | 92,926,000 | 5.62% | 0.01% |
| Sept. 2, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 5000 | $32.10 | 96,270.0000 | 92,926,000 | 4.94% | 0.01% |
| Sept. 2, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 5000 | $16.89 | 101,270.0000 | 92,926,000 | 5.19% | 0.01% |
| Aug. 22, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock Option (Right to Buy) | 30000 | $0.00 | 89,042.0000 | 92,926,000 | 25.20% | 0.03% |
| Aug. 22, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 30000 | $16.89 | 96,270.0000 | 92,926,000 | 45.27% | 0.03% |
| Aug. 22, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 30000 | $30.43 | 66,270.0000 | 92,926,000 | 31.16% | 0.03% |
| Aug. 20, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 6492 | $29.18 | 66,270.0000 | 92,926,000 | 8.92% | 0.01% |
| March 19, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 2388 | $34.17 | 72,360.0000 | 92,926,000 | 3.19% | 0.00% |
| March 19, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 127 | $34.83 | 72,233.0000 | 92,926,000 | 0.18% | 0.00% |
| Feb. 20, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | A | Common Stock | 43000 | $0.00 | 74,748.0000 | 92,926,000 | 135.44% | 0.05% |
| Feb. 20, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | A | Stock Option (Right to Buy) | 65000 | $0.00 | 65,000.0000 | 92,926,000 | 9999.99% | 0.07% |
| Feb. 3, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock option (Right to Buy) | 5000 | $0.00 | 119,042.0000 | 92,926,000 | 4.03% | 0.01% |
| Feb. 3, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 5000 | $16.89 | 36,748.0000 | 92,926,000 | 15.75% | 0.01% |
| Feb. 3, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 5000 | $39.07 | 31,748.0000 | 92,926,000 | 13.61% | 0.01% |
| Jan. 7, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock Option (Right to Buy) | 2500 | $0.00 | 18,500.0000 | 92,926,000 | 11.90% | 0.00% |
| Jan. 3, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 15000 | $16.89 | 44,248.0000 | 92,926,000 | 51.29% | 0.02% |
| Jan. 3, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 15000 | $52.09 | 29,248.0000 | 92,926,000 | 33.90% | 0.02% |
| Jan. 7, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 2500 | $19.64 | 31,748.0000 | 92,926,000 | 8.55% | 0.00% |
| Jan. 3, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock option (Right to Buy) | 15000 | $0.00 | 124,042.0000 | 92,926,000 | 10.79% | 0.02% |
| Oct. 3, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 14375 | $54.63 | 28,507.0000 | 68,175,000 | 33.52% | 0.02% |
| Oct. 3, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 14375 | $16.89 | 42,882.0000 | 68,175,000 | 50.43% | 0.02% |
| Oct. 3, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock option (Right to Buy) | 14375 | $0.00 | 139,042.0000 | 68,175,000 | 9.37% | 0.02% |
| July 3, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 14375 | $44.87 | 28,507.0000 | 68,175,000 | 33.52% | 0.02% |
| July 3, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 14375 | $16.89 | 42,882.0000 | 68,175,000 | 50.43% | 0.02% |
| July 3, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock option (Right to Buy) | 14375 | $0.00 | 153,417.0000 | 68,175,000 | 8.57% | 0.02% |
| June 24, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 9500 | $16.89 | 37,286.0000 | 68,175,000 | 34.19% | 0.01% |
| June 24, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock option (Right to Buy) | 9500 | $0.00 | 167,792.0000 | 68,175,000 | 5.36% | 0.01% |
| June 24, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 9500 | $45.73 | 27,786.0000 | 68,175,000 | 25.48% | 0.01% |
| April 15, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 14375 | $16.89 | 42,161.0000 | 68,175,000 | 51.73% | 0.02% |
| April 15, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock option (Right to Buy) | 14375 | $0.00 | 177,292.0000 | 68,175,000 | 7.50% | 0.02% |
| April 15, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 14375 | $44.47 | 27,786.0000 | 68,175,000 | 34.10% | 0.02% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 714 | $43.69 | 27,786.0000 | 68,175,000 | 2.51% | 0.00% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 4375 | $45.89 | 28,500.0000 | 68,175,000 | 13.31% | 0.01% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 4375 | $16.89 | 32,875.0000 | 68,175,000 | 15.35% | 0.01% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock Option (right to buy) | 10000 | $0.00 | 191,667.0000 | 68,175,000 | 4.96% | 0.01% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Stock Option (right to buy) | 4375 | $0.00 | 201,667.0000 | 68,175,000 | 2.12% | 0.01% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 10000 | $43.28 | 28,500.0000 | 68,175,000 | 25.97% | 0.01% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 10000 | $16.89 | 38,500.0000 | 68,175,000 | 35.09% | 0.01% |
| March 18, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | F | Common Stock | 411 | $38.14 | 28,500.0000 | 68,175,000 | 1.42% | 0.00% |
| March 4, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | A | Common Stock | 23000 | $0.00 | 28,911.0000 | 68,175,000 | 389.11% | 0.03% |
| March 4, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | A | Stock Option (right to buy) | 87000 | $0.00 | 87,000.0000 | 68,175,000 | 9999.99% | 0.13% |
| Jan. 3, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Non-qualified stock option (Right to Buy) | 14375 | $0.00 | 206,042.0000 | 68,175,000 | 6.52% | 0.02% |
| Jan. 3, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 14375 | $16.89 | 20,286.0000 | 68,175,000 | 243.19% | 0.02% |
| Jan. 3, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 14375 | $35.00 | 5,911.0000 | 68,175,000 | 70.86% | 0.02% |
| Dec. 21, 2023 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Common Stock | 9583 | $16.89 | 15,494.0000 | 32,344,371,000 | 162.12% | 0.00% |
| Dec. 21, 2023 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | S | Common Stock | 9583 | $34.57 | 5,911.0000 | 32,344,371,000 | 61.85% | 0.00% |
| Dec. 21, 2023 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Med and Dev Officer | M | Non-qualified stock option (Right to Buy) | 9583 | $0.00 | 220,417.0000 | 32,344,371,000 | 4.17% | 0.00% |
| April 3, 2023 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Development Officer | F | Common Stock | 4288 | $15.98 | 12,712.0000 | 0 | 25.22% | 0.00% |
| April 5, 2023 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Development Officer | S | Common Stock | 8212 | $16.15 | 4,500.0000 | 0 | 64.60% | 0.00% |
| March 1, 2023 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Development Officer | A | Common Stock | 4500 | $0.00 | 17,000.0000 | 0 | 36.00% | 0.00% |
| March 1, 2023 | Crinetics Pharmaceuticals, Inc. | $CRNX | Pizzuti Dana | Chief Development Officer | A | Stock Option (right to buy) | 21000 | $0.00 | 21,000.0000 | 0 | 9999.99% | 0.00% |